Acromegaly is usually caused by a noncancerous tumor. Middle-aged adults are most commonly affected. Symptoms include enlargement of the face, hands, and feet. Prompt treatment is needed to avoid serious illness. Drugs can reduce the effects of growth hormone. If needed, surgery and radiation may be used to remove tumor cells.
MAR002 is an early, promising development: a new take on a proven strategy, with the potential for stronger IGF-1 control and dramatically less frequent dosing. At the same time, it’s important to keep expectations grounded. The drug is still investigational. It is not approved, not yet available outside clinical trials, and a larger patient study is needed to confirm what the early data suggest.
Today’s podcast is about our super athlete friend Risa August and her new book about her acromegaly experience, her life, and her 1,800 mile ride from Canada to Mexico.
From J D Faccinetti, Co-founder and Chief Editor – When you deal with a chronic pituitary disease, you get close to your medications, just like you would to a friend. This was my experience with
Today, Dr. Scott Struthers talks to PWN about paltusotine, their new once-a-day oral drug candidate, which recently completed phase 3 of the clinical trial.
San Diego, California-based Crinetics Pharmaceutical announced today that its novel investigational drug paltusotine maintained IGf-1 levels in patients who switched from monthly injectables
This year, the Acromegaly Community, a US-based advocacy organization for patients and families dealing with the disease, is organizing regional meetings. These regional meetings are a change from prior years, where the community presented a
After a few virtual meetings these past years, I was back at UC Berkeley/UCSF’s joint medical program for an in-person gathering with some of the brightest and most engaged medical students on the planet. This is, without a doubt, one of my favorite things to do since founding PWN, and I look forward to it every year.
Meet Laura Cheng. Laura is a nurse. She has acromegaly. She works as a clinical nurse and is currently enrolled in the endocrine program at Duke University.
This book, edited by world-renowned clinicians and editors Dr. Manish Aghi and Dr. Lewis Blevins, delivers a guide to medical decision-making on diagnosing and treating acromegaly.
We take advantage of Acromegaly Day, coming up on November 1, to highlight resources from industry partners. The Pfizer Patient Affairs Liaisons (PALs) connect patients and caregivers affected by rare conditions with programs and information. PALs work with
This is a highly informative presentation on the subtleties of the medical management of this complicated disease direct from the clinical practices of one of the best most experienced physicians treating acromegaly patients today.
We continue to showcase Pfizer’s new series on patient support. This brochure offers great advice on how to deal with a new acromegaly diagnosis. The materials provide valuable content given the importance of proper disease
In January 2021, the Acromegaly Community, a US-based patient advocacy organization, organized and participated in an externally lead patient focus drug development meeting. The EL-PFDD initiative is a Food and Drug Administration (FDA) effort to systematically